Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or in ...
Post-COVID-19 condition (PCC) involves persistent symptoms like fatigue and cognitive dysfunction, affecting 8.4% of US adults. A randomized clinical trial showed cognitive and behavioral ...
Alzheimer’s disease and related dementias were less likely among adults who completed cognitive speed training with booster sessions, according to data published in Alzheimer’s & Dementia: ...
A recent neuropsychological evaluation diagnosis impugned several controversial theories about anesthesia and cognitive decline. As a medicinal therapy to relieve pain and brain dysfunction, ...
Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...
People with dementia have protein build-up in astrocytes that may trigger abnormal antiviral activity and memory loss, according to a preclinical study by a team of Weill Cornell Medicine ...
Table 1. Summary of medical therapy (chemotherapy and aromatase inhibitors) and measurements of cognitive functioning (neuropsychological testing and functional imaging) and potential confounders ...
People with dementia have protein build-up in astrocytes that may trigger abnormal antiviral activity and memory loss, according to a preclinical study. People with dementia have protein build-up in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results